89bio announces closing enrollment in phase 1b/2a nash trial

89bio announces closing of enrollment in its phase 1b/2a nash trial and reports new preclinical data confirming bio89-100’s mechanism of action via potent fgf receptor agonism.89bio inc - reaffirms guidance for nash trial topline data in 2h20.89bio inc - plans to initiate phase 2b trial in first half of 2021.89bio inc - delaying initiation of its phase 2 trial of bio89-100 for treatment of shtg, which was planned for first half of 2020.
ETNB Ratings Summary
ETNB Quant Ranking